ASCO 2015 Update: Releasing the Potential of the Immune System
The Annual Meeting of the American Society of Clinical Oncology (ASCO) provides an opportunity for thousands of oncologists and healthcare professionals to receive research updates and exchange ideas surrounding trends in cancer treatments. More than 30,000 attend each year, making it one of the largest educational and scientific conferences dedicated to advancing cancer care. I recently joined my colleagues for the ASCO 2015 Annual Meeting, where a focus was on breakthroughs in immunotherapy.
What is Immunotherapy?
Immunotherapy refers to treatments that prompt the human body’s immune system to attack cancer cells. Cancer occurs when a genetic mutations occurs that causes a healthy cell to become cancerous. Can the immune system recognize these […]
The Breast Cancer Index (BCI) is a test that analyzes a breast cancer patient’s genes. In women with estrogen receptor-positive (ER-positive) breast cancer, BCI predicts risk of recurrence beyond five years and predicts how likely a 
[…]
Kadcyla, approved by the U.S. Food and Drug Administration (FDA) in February 2013, is one of the latest advancements to improve our ability to treat breast cancer. Although Kadcyla was only approved for a specific population of breast cancer patients (HER2 positive breast cancer that has spread to other parts of the body (metastatic breast cancer)), it fits into a larger story that is fundamentally changing how we treat many types of breast cancer.
